Price History

Hover for the daily close. The dotted line marks the period open.

Compare IFRX with… →

IFRX Key Statistics

As of Sep 4, 2026

Trading

Open: $2.21
Previous Close: $2.23
Day's Range: 2.16–2.38
52-Week Range: 0.80–2.95
Volume: 393.90K
Beta: 2.54

Valuation

Market Cap: $327.16M
P/E Ratio: unprofitable
EPS (ttm): −0.57

Financials (FY)

Revenue (FY): $29.33K−82.31%
Net Income (FY): −$45.63M
Profit margin: 0.00%
Shares Outstanding: 147.37M
1-Year Return: +41.40%

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 1.11M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IFRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−89.11%+119.80%

2017*201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+119.80%
2025	−59.11%
2024	+51.53%
2023	−47.42%
2022	−34.87%
2021	−5.37%
2020	+27.02%
2019	−89.11%
2018	+73.60%
2017 (partial year)	+39.67%

As of September 4, 2026.

IFRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$29.33K	−$45.63M	−155582.1%
2024	$165.79K	−$46.06M	−27785.0%
2023	$63.09K	−$42.67M	−67630.7%
2022	$0.00	−$29.48M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$29.33K	−$7.24M	−$48.26M	−$45.63M	−155582.1%
2024	$165.79K	−$3.15M	−$52.91M	−$46.06M	−27785.0%
2023	$63.09K	−$469.17K	−$44.59M	−$42.67M	−67630.7%
2022	$0.00	$0.00	−$32.24M	−$29.48M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IFRX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	IFRX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

InflaRx N.V. Common Stock (IFRX) carries a market capitalisation of $327.16M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 65.

The 52-week range on file runs from $0.80 to $2.95. The most recent close on file for IFRX is $2.22, dated September 4, 2026. That is −$0.01 (−0.45%) against the previous close. The latest close sits 178.2% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $29.33K. That is −82.31% against the prior fiscal year, when revenue was $165.79K. The same year closed with a net loss of $45.63M. The reported profit margin is 0%. Trailing earnings per share are −0.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $29.33K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.54. Annualized volatility over the trailing 8 years is 106.94%. The trailing one-year price return is +41.40%. Across 5 years the annualized return works out at −3.04%.

Growth & Income

No dividend is on file for IFRX.

So far in 2026 the price is +119.80%. The strongest complete calendar year on file is 2018 at +73.60%; the weakest is 2019 at −89.11%. Of the 8 complete calendar years on file, 3 finished higher.

Peer Comparison

InflaRx N.V. Common Stock (IFRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
InflaRx N.V. Common Stock	IFRX	$327.16M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. InflaRx N.V. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About InflaRx N.V. Common Stock

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Visit website →

InflaRx N.V. Common Stock (IFRX) Stock Analysis